TCM Biotech International Corp.

TPEX:4169 Stock Report

Market Cap: NT$3.4b

TCM Biotech International Future Growth

Future criteria checks 0/6

TCM Biotech International's EPS is expected to grow by 110.3% per annum.

Key information

n/a

Earnings growth rate

110.3%

EPS growth rate

Biotechs earnings growth51.7%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Can You Imagine How TCM Biotech International's (GTSM:4169) Shareholders Feel About The 28% Share Price Increase?

Jan 31
Can You Imagine How TCM Biotech International's (GTSM:4169) Shareholders Feel About The 28% Share Price Increase?

Key Things To Consider Before Buying TCM Biotech International Corp. (GTSM:4169) For Its Dividend

Jan 04
Key Things To Consider Before Buying TCM Biotech International Corp. (GTSM:4169) For Its Dividend

We Think TCM Biotech International (GTSM:4169) Can Stay On Top Of Its Debt

Dec 07
We Think TCM Biotech International (GTSM:4169) Can Stay On Top Of Its Debt

Earnings and Revenue Growth Forecasts

TPEX:4169 - Analysts future estimates and past financials data (TWD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20241,08234-10-51
6/30/2024834204750N/A
3/31/20249021926N/A
12/31/202397019-42-38N/A
9/30/202393216-13-7N/A
6/30/2023895131724N/A
3/31/2023849163238N/A
12/31/2022802184752N/A
9/30/2022761134045N/A
6/30/202272083438N/A
3/31/202271152126N/A
12/31/20217022815N/A
9/30/2021694-2-23-10N/A
6/30/2021686-5-53-34N/A
3/31/202171210020N/A
12/31/2020737265375N/A
9/30/2020719347288N/A
6/30/20207004291101N/A
3/31/2020635243240N/A
12/31/20195697-28-21N/A
9/30/201956410-28-6N/A
6/30/201956013-289N/A
3/31/201955019-2318N/A
12/31/201854025-1827N/A
9/30/201853422-3112N/A
6/30/201852719-44-2N/A
3/31/201853419N/A30N/A
12/31/201754119N/A63N/A
9/30/201753522N/A32N/A
6/30/201752925N/A2N/A
3/31/201751829N/A-35N/A
12/31/201650633N/A-71N/A
9/30/201649432N/A-39N/A
6/30/201648331N/A-7N/A
3/31/201647626N/A2N/A
12/31/201547021N/A12N/A
9/30/201543025N/AN/AN/A
6/30/201539029N/A52N/A
3/31/201535229N/A51N/A
12/31/201431429N/A50N/A
9/30/201432329N/AN/AN/A
6/30/201433329N/A17N/A
3/31/201432422N/A15N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 4169's forecast earnings growth is above the savings rate (1.1%).

Earnings vs Market: Insufficient data to determine if 4169's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 4169's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 4169's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 4169's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 4169's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 18:54
End of Day Share Price 2024/12/31 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TCM Biotech International Corp. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullKGI Securities Co. Ltd.
Hsuan ChenKGI Securities Co. Ltd.